Tsui J, Leroux B, Radick A, Schramm Z, Blalock K, LaBelle C
Drug Alcohol Depend. 2021; 227:108917.
PMID: 34399136
PMC: 8464515.
DOI: 10.1016/j.drugalcdep.2021.108917.
Schramm Z, Leroux B, Radick A, Ventura A, Klein J, Samet J
Addict Sci Clin Pract. 2020; 15(1):30.
PMID: 32736660
PMC: 7393902.
DOI: 10.1186/s13722-020-00203-9.
Godersky M, Klein J, Merrill J, Blalock K, Saxon A, Samet J
J Addict Med. 2020; 14(4):319-325.
PMID: 31972762
PMC: 7358111.
DOI: 10.1097/ADM.0000000000000608.
Godersky M, Saxon A, Merrill J, Samet J, Simoni J, Tsui J
Addict Sci Clin Pract. 2019; 14(1):11.
PMID: 30867068
PMC: 6417248.
DOI: 10.1186/s13722-019-0139-3.
Hauser K, Knapp P
Front Pediatr. 2018; 5:294.
PMID: 29410949
PMC: 5787058.
DOI: 10.3389/fped.2017.00294.
Buprenorphine Prescribing: To Expand or Not to Expand.
Li X, Shorter D, Kosten T
J Psychiatr Pract. 2016; 22(3):183-92.
PMID: 27123798
PMC: 4852384.
DOI: 10.1097/PRA.0000000000000154.
Motivations for prescription drug misuse among young men who have sex with men (YMSM) in Philadelphia.
Kecojevic A, Corliss H, Lankenau S
Int J Drug Policy. 2015; 26(8):764-71.
PMID: 25936445
PMC: 4499499.
DOI: 10.1016/j.drugpo.2015.03.010.
Risk factors for high levels of prescription drug misuse and illicit drug use among substance-using young men who have sex with men (YMSM).
Kecojevic A, Wong C, Corliss H, Lankenau S
Drug Alcohol Depend. 2015; 150:156-63.
PMID: 25772436
PMC: 6368938.
DOI: 10.1016/j.drugalcdep.2015.02.031.
Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.
Fitting S, Zou S, El-Hage N, Suzuki M, Paris J, Schier C
Curr HIV Res. 2015; 12(6):424-34.
PMID: 25760046
PMC: 4475822.
DOI: 10.2174/1570162x1206150311161147.
[Misuse of opioid analgesics. An internet analysis].
Kruger R, Meissner W, Zimmer A
Schmerz. 2014; 28(5):473-82.
PMID: 25106826
DOI: 10.1007/s00482-014-1466-7.
Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland.
Genberg B, Gillespie M, Schuster C, Johanson C, Astemborski J, Kirk G
Addict Behav. 2013; 38(12):2868-73.
PMID: 24018232
PMC: 3805723.
DOI: 10.1016/j.addbeh.2013.08.008.
Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
Sohler N, Weiss L, Egan J, Lopez C, Favaro J, Cordero R
J Opioid Manag. 2013; 9(2):111-9.
PMID: 23709320
PMC: 4012752.
DOI: 10.5055/jom.2013.0152.
A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.
Balhara Y, Jain R
Innov Clin Neurosci. 2012; 9(7-8):24-9.
PMID: 22984649
PMC: 3442748.
Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
Bazazi A, Yokell M, Fu J, Rich J, Zaller N
J Addict Med. 2011; 5(3):175-80.
PMID: 21844833
PMC: 3157053.
DOI: 10.1097/ADM.0b013e3182034e31.
Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
Moratti E, Kashanpour H, Lombardelli T, Maisto M
Clin Drug Investig. 2010; 30 Suppl 1:3-11.
PMID: 20450240
DOI: 10.2165/11536020-000000000-00000.
Opioids and the treatment of chronic pain: controversies, current status, and future directions.
Rosenblum A, Marsch L, Joseph H, Portenoy R
Exp Clin Psychopharmacol. 2008; 16(5):405-16.
PMID: 18837637
PMC: 2711509.
DOI: 10.1037/a0013628.
